Associated Papers
Innovative Drug and Prodrug Candidates in Cancer Treatment Targeting TP53 Mutations: Challenge and Hope.
Al-Zoubi RM et al.
Drug Development Research, 2026
Evaluation of non-canonical p53 functions in DNA replication and recombination for variant classification.
Jansche R et al.
Cell Death & Disease, 2026
Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors.
Dumbrava EE et al.
The New England Journal of Medicine, 2026
Characterizing Longitudinal Molecular Changes in ctDNA in Patients with Metastatic Castration-resistant Prostate Cancer.
Jani CT et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
Partial truncation of the C-terminal domain of PTCH1 in cancer promotes tumourigenesis by non-canonical activation of a GLI-PI3K loop.
Caballero-Ruiz B et al.
Oncogene, 2026
A case of ovarian Sertoli-Leydig cell tumor with high grade transformation harbouring DICER1 and TP53 mutations.
Němejcová K et al.
Virchows Archiv : an International Journal of Pathology, 2026
Non-hydrolyzable acetyllysine analogs to study protein acetylation in vitro and in cells.
Kienle SM et al.
Nature Communications, 2026
Lung cancer-enriched p53 mutants occupy canonical p53 target genes without activating transcription, revealing a distinct loss-of-function behavior.
Tracewell MA et al.
Biorxiv : the Preprint Server for Biology, 2026
Long-term administration of the mutant IDH inhibitor DS-1001b suppresses the growth of IDH1-mutant glioma in vitro and in mouse xenograft models and alters epigenetic profiles.
Fujimoto K et al.
Acta Neuropathologica, 2026
Analysis of genetic mutation characteristics in 40 Chinese patients with hepatocellular carcinoma.
Xu S et al.
Genes & Genomics, 2026
Health Care Impact of Comprehensive Genomic Profiling of Solid Tumors in Patient Management Using POWER (Precision Oncology at Western University).
Bhai P et al.
The Journal of Molecular Diagnostics : Jmd, 2026
Bile Acid-Induced Aggregation and Phase Separation of Mutant p53 Leads to Doxorubicin Sequestration.
Kaur H et al.
Biomacromolecules, 2026
Mutant p53 disrupts antioxidant defense in fallopian tube epithelium via GSTAs suppression: A pathway to serous tubal carcinogenesis.
Burnett DB et al.
Free Radical Biology & Medicine, 2026
Correlation between P53 immunohistochemical staining and TP53 molecular testing in endometrial carcinomas: a detailed assessment of discrepant cases with implications for patient management.
Machuca-Aguado J et al.
Histopathology, 2026
Mutant p53 Regulates Pyruvate Dehydrogenase Kinase 1 (PDK1) to Promote Proliferation and Migration in Breast Cancer.
Ye Y et al.
Cancer Science, 2026
Genomic Profiling of Pediatric Solid Tumors With a Dual DNA/RNA Panel: JCCG-TOP2 Study.
Tao K et al.
Cancer Science, 2026
Linking p53 rs1042522 Variant to Thyroid Cancer Risk: Insights from a Comprehensive Meta-Analysis of 2116 Cases.
Vakili-Ojarood M et al.
Cancer Investigation, 2026
Next-Generation Sequencing-Based Detection of KRAS G12D Variants in Colorectal Cancer: A Retrospective Cohort Study.
Hekimoglu G et al.
Genes, 2026
TP53 mutation predict poor prognosis in diffuse large B-cell lymphoma: a single-center study.
Zhang H et al.
Annals of Hematology, 2026
Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD+ to eradicate KRAS-driven AML.
Jia A et al.
Cell Metabolism, 2026
Genomic enrichment and functional impact of TP53 and CYLD alterations in recurrent and metastatic HPV-associated head and neck cancer.
Prasad M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
AI-Guided Conformational Dynamics of p53 L1 Loop Reveal an Allosteric Switch Regulating DNA Binding and Cancer Hotspots.
Navarro Acero P et al.
Journal of Chemical Information and Modeling, 2026
Common gene mutations in 103 authenticated colorectal cancer cell lines.
Kranjec C et al.
Oncogenesis, 2026
Oncogenic p53 induces mitotic errors in lung cancer cells by recopying DNA replication forks conferring targetable proliferation advantage.
Singh S et al.
Cell Death and Differentiation, 2026
CP-31398 restored the functional condensates of R175H p53 by stabilizing the zinc-binding domain and 251-258 segment.
Liu Y et al.
Colloids and Surfaces. B, Biointerfaces, 2026
Correlation analysis of TP53 missense mutations and p53 protein expression patterns in endometrial carcinoma.
Yang Y et al.
Human Pathology, 2026
Dominant-negative TP53 mutations potentiated by the HSF1-regulated proteostasis network.
Halim S et al.
Molecular Cell, 2026
TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma.
Liu S et al.
Annals of Hematology, 2026
ΔNp73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia.
Pereira-Martins DA et al.
Cell Reports. Medicine, 2026
Dual Targeting of Mutant p53 and SNRPD2 via Engineered Exosomes Modulates Alternative Splicing to Suppress Ovarian Cancer.
Zhao W et al.
Advanced Science (weinheim, Baden-wurttemberg, Germany), 2026
A framework for the molecular identification of CHIP for clinical research.
Harraka P et al.
Hgg Advances, 2026
Construction of Small-Molecule Deubiquitinase-Targeting Chimeras to Reactivate and Stabilize Mutant p53 Y220C in Vitro and in Vivo.
He C et al.
Angewandte Chemie (international Ed. in English), 2026
FBXO11 suppression rewires an NPM1-centered interactome influencing the progression of myelodysplastic syndrome.
Niederkorn M et al.
The Journal of Clinical Investigation, 2026
Development of an APC and TP53-based duplex sequencing assay to positively predict colorectal cancer response to anti-EGFR therapy.
Yang M et al.
Cellular Oncology (dordrecht, Netherlands), 2026
T cell receptor-engineered T cells targeting the TP53R248Q neoantigen elicit antitumor effects in human cancer models.
Shen L et al.
The Journal of Clinical Investigation, 2026
Restoration of the Y220C p53 Full-Length Mutant by PK11000: a Molecular Dynamics Study of an Intrinsically Disordered Protein.
Stetson S et al.
Acs Omega, 2026
Ultra-deep duplex sequencing reveals unique features of somatic evolution in the normal tissues of a family with Li-Fraumeni syndrome.
Colegrove HL et al.
Biorxiv : the Preprint Server for Biology, 2026
Genetic Profiling of Mammary Periductal Stromal Tumors With Histologic Correlation Highlights High-Grade and Low-Grade Groups and Similarities to Phyllodes Tumors.
Krings G et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2026
Remarkable response of gastric adenocarcinoma with FGFR2-TRIM44 fusion to pemigatinib: a case report.
Fujiwara M et al.
Japanese Journal of Clinical Oncology, 2026
Acquired on-target alterations drive clinical resistance to p53-Y220C reactivators.
Fece de la Cruz F et al.
Cancer Discovery, 2026
APOBEC3C coordinates DDX5 in R-loop resolution and dynamic control of Chk1-mediated stress-responsive circuitry as a prerequisite for gemcitabine resistance in p53-deficient cells.
Tao L et al.
Cell Death & Disease, 2026
Phylogenomics to structure: evolutionary and clinical signals in the TP53 DNA-binding core through LOOCV-validated ensemble learning.
Raza Abbas S et al.
Briefings in Bioinformatics, 2026
Inhibition of GPX4 induces the death of p53-mutant triple-negative breast cancer cells.
Tahaney WM et al.
Breast Cancer Research and Treatment, 2026